Agarwal B R, Gulvady A, Bhalla K, Dalvi R, Currimbhoy Z E
Department of Pediatrics Hematology and Oncology, B.J. Wadia Hospital for Children, Bombay.
Indian Pediatr. 1995 Oct;32(10):1061-5.
Severe aplastic anemia (SAA) in children has been previously treated with high dose methyl prednisolone (HDMP) with favorable results. We reviewed our experience with intravenous HDMP. Seven children with a diagnosis of SAA confirmed on bone marrow biopsy were treated with 300 mg/kg total dose of intravenous HDMP over a 4 week period. Patients were closely monitored for response and side effects. HDMP was well tolerated except for hyperglycemia in one case. Six of the seven patients showed no response to HDMP. This observation is in stark contrast with previous trials on use of HDMP in SAA. It is concluded that HDMP should be reserved only for patients with milder bone marrow hypoplasia.
儿童重型再生障碍性贫血（SAA）此前采用大剂量甲基泼尼松龙（HDMP）治疗，效果良好。我们回顾了静脉注射HDMP的经验。7名经骨髓活检确诊为SAA的儿童在4周内接受了总量为300mg/kg的静脉HDMP治疗。密切监测患者的反应和副作用。除1例出现高血糖外，HDMP耐受性良好。7名患者中有6名对HDMP无反应。这一观察结果与先前关于HDMP用于SAA的试验形成鲜明对比。结论是HDMP应仅保留用于骨髓发育不全较轻的患者。
